Autologous bone marrow-derived mononuclear cells (BM-MNCs) are extracted from patient bone marrow and processed before being infused locally at the site of diseased vascular tissue in the lower limb. Our candidate therapies contains endothelial progenitors, mesenchymal stem cells and supporting haematopoietic stem cells which potentially promote neovascularisation in patients. Whereas conventional drug therapies typically only address the symptoms of the disease, cellular therapies target the underlying cause of the disease to induce revascularisation of the affected limb, alleviating ischemia, promoting wound healing and improving of clinical outcome.
Our first BM-MNCs therapy candidate, REX-001, consists of processed bone marrow and has been shown in clinical trials to stimulate vascular regrowth and alleviate the serious symptoms of the disease including ulceration, ischemia and improve patient quality of life.
We are also conducting clinical development with an additional bone marrow derived cellular therapy, REX-003, which is a cellular therapy product that has been enriched for cells expressing CD133. CD133 is a marker of early endothelial progenitor cell phenotype and therefore enrichment of these cells is expected to enhance the clinical efficacy of the product.